ATR and metastatic melanoma: In NSCLC, bemcentinib combined with VX-970 (an ATR inhibitor) enhanced DNA damage and replication stress, increasing susceptibility to ATR inhibitors.172 In addition, in metastatic melanoma, bemcentinib improved the therapeutic efficacy of the BRAF inhibitor vemurafenib by triggering apoptosis, accelerating ferroptosis, and reducing autophagy.243 In older AML patients who cannot tolerate intense chemotherapy, bemcentinib showed an anti-leukemic effect when combined with low-dose cytarabine or decitabine (NCT02488408).